In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth

Diagnostic Microbiology and Infectious Disease

Volumn 59, Issue 3, 2007, Pages 347-349

  Petersen, Peter J ^a   Jones, C Hal ^a   Bradford, Patricia A ^a  

^a WYETH RESEARCH   (United States)

Author keywords

Bactericidal; Bacteriostatic; Tigecycline

Indexed keywords

IMIPENEM; TIGECYCLINE; VANCOMYCIN;

ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM COLONY; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE AEROBIC RODS AND COCCI; GRAM-POSITIVE COCCI; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; VANCOMYCIN;

EID: 35548972097     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2007.05.013     Document Type: Article

References (14)

1. Bradford P.A., Petersen P.J., Young M., Jones C.H., Tischler M., and O'Connell J. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent Oxyrase to standardize the test method. Antimicrob. Agents Chemother. 49 (2005) 3903-3909
2. CDC. Vancomycin-resistant Staphylococcus aureus- NewYork, 2004. Morb. Mortal Wkly. Rep. 53 (2004) 322-323
3. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards: M7-A7 (2006), Clinical and Laboratory Standards Institute, Wayne, PA
4. CLSI. Performance standards for antimicrobial susceptibility testing: M100-S16, Sixteenth informational supplement (2006), Clinical Laboratory Standards Institute, Wayne, PA 26
5. Connell S.R., Tracz D.M., Nierhaus K.D., and Taylor D.E. Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrob. Agents Chemother. 47 (2003) 3675-3681
6. Goldstein E.J., and Garabedian-Ruffalo S.M. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin. Infect. Dis. 35 (2002) 1505-1511
7. Jacobs M.R., and Johnson C.E. Macrolide resistance: an increasing concern for treatment failure in children. J. Ped. Infect. Dis. 22 8 Suppl (2003) S131-S138
8. Li X.Z., and Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 64 (2004) 159-204
9. NCCLS. Methods for determining bactericidal activity of antimicrobial agents: Approved guideline M26-A (1999), National Committee for Clinical Laboratory Standards, Wayne, PA 19
10. Pankey G.A., and Sabath L.D. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin. Infect. Dis. 38 (2004) 864-870
11. Petersen P.J., and Bradford P.A. Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent Oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob. Agents Chemother. 49 (2005) 3910-3918
12. Petersen P.J., Jacobus N.V., Weiss W.J., Sum P.E., and Testa R.T. In vitro and in vivo antimicrobial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43 (1999) 738-744
13. Petersen P.J., Wang T.Z., Dushin R.G., and Bradford P.A. Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against gram-positive clinical isolates. Antimicrob. Agents Chemother. 48 (2004) 739-746
14. Sum P.-E., and Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg. Med. Chem. Lett. 9 (1999) 1459-1462